http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Treatment of Elastosis Perforans Serpiginosa with the 585-nm Pulsed-dye Laser
( Yeon Gu Choi ),( Sang Yeon Kim ),( Ji Soo Park ),( Kyu Yeon Kim ),( Bo Bin Cha ),( Jin Seop Kim ),( Gyoo Huh ),( Heun Joo Lee ),( Young Jun Choi ),( Won-serk Kim ),( Ga-young Lee ) 대한피부과학회 2022 대한피부과학회 학술발표대회집 Vol.73 No.2
Jung, Yeon Joo,Kim, Kyung-Chul,Heo, Jun-Young,Jing, Kaipeng,Lee, Kyung Eun,Hwang, Jun Seok,Lim, Kyu,Jo, Deog-Yeon,Ahn, Jae Pyoung,Kim, Jin-Man,Huh, Kang Moo,Park, Jong-Il Korean Society for Molecular and Cellular Biology 2015 Molecules and cells Vol.38 No.7
hBMSCs are multipotent cells that are useful for tissue regeneration to treat degenerative diseases and others for their differentiation ability into chondrocytes, osteoblasts, adipocytes, hepatocytes and neuronal cells. In this study, biodegradable elastic hydrogels consisting of hydrophilic poly(ethylene glycol) (PEG) and hydrophobic poly(${\varepsilon}$-caprolactone) (PCL) scaffolds were evaluated for tissue engineering because of its biocompatibility and the ability to control the release of bioactive peptides. The primary cultured cells from human bone marrow are confirmed as hBMSC by immunohistochemical analysis. Mesenchymal stem cell markers (collagen type I, fibronectin, CD54, $integrin1{\beta}$, and Hu protein) were shown to be positive, while hematopoietic stem cell markers (CD14 and CD45) were shown to be negative. Three different hydrogel scaffolds with different block compositions (PEG:PCL=6:14 and 14:6 by weight) were fabricated using the salt leaching method. The hBMSCs were expanded, seeded on the scaffolds, and cultured up to 8 days under static conditions in Iscove's Modified Dulbecco's Media (IMDM). The growth of MSCs cultured on the hydrogel with PEG/PCL= 6/14 was faster than that of the others. In addition, the morphology of MSCs seemed to be normal and no cytotoxicity was found. The coating of the vascular endothelial growth factor (VEGF) containing scaffold with Matrigel slowed down the release of VEGF in vitro and promoted the angiogenesis when transplanted into BALB/c nude mice. These results suggest that hBMSCs can be supported by a biode gradable hydrogel scaffold for effective cell growth, and enhance the angiogenesis by Matrigel coating.
Kim, Yeon-Joo,Park, Won,Ha, Boram,Park, Boram,Joo, Jungnam,Kim, Tae Hyun,Park, In Hae,Lee, Keun Seok,Lee, Eun Sook,Shin, Kyung Hwan,Kim, Haeyoung,Yu, Jeong Il,Choi, Doo Ho,Huh, Seung Jae,Wee, Chan Woo 대한암학회 2017 Cancer Research and Treatment Vol.49 No.4
<P><B>Purpose</B></P><P>The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. </P><P><B>Materials and Methods</B></P><P>We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. </P><P><B>Results </B></P><P>We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).</P><P><B>Conclusion </B></P><P>PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.</P>
The Advances of Laparoscopic Gastrectomy for Gastric Cancer
Huh, Yeon-Ju,Lee, Joo-Ho Hindawi 2017 Gastroenterology Research and Practice Vol.2017 No.-
<P>Laparoscopic gastrectomy is evolving. With the increasing expertise and experience of oncologic surgeons in the minimally invasive surgery for gastric cancer, the indication for laparoscopic gastrectomy is expanding to advanced cases. Many studies have demonstrated the benefits of minimally invasive surgery, including reduced risk of surgery-related injury, reduced blood loss, less pain, and earlier recovery. In order to establish concrete evidence for the suitability of minimal invasive surgery for gastric cancer, many multicenter RCTs, comparing the short- and long-term outcomes of laparoscopic versus open surgery, are in progress. Advances in laparoscopic gastrectomy are moving toward increasingly minimally invasive approaches that enable the improvement of the quality of life of patients, without compromising on oncologic safety.</P>